Prognostic Impact of Caspase-8, CDK9 and Phospho-CDK9 (Thr 186) Expression in Patients with Uterine Cervical Cancer Treated with Definitive Chemoradiation and Brachytherapy.

Introduction: After primary platinum-based chemoradiation of locally advanced uterine cervical cancer, a substantial proportion of women present with persistent, recurrent or metastatic disease, indicating an unmet need for biomarker development. Methods: We evaluated the clinical records of 69 cervical cancer patients (Federation of Gynecology and Obstetrics, FIGO Stage > IB3) who were subjected to definitive CRT. Immunohistochemical scoring of caspase-8, cyclin dependent kinase 9 (CDK9) and phosphorylated (phospho-)CDK9 (threonine (Thr) 186) was performed on pretreatment samples and correlated with the histopathological and clinical endpoints, including relapse-free survival (RFS), distant metastasis-free survival (DMFS), cancer-specific survival (CSS) and overall survival (OS). Results: Lower levels of caspase-8 were more prevalent in patients with a higher T-stage ( p = 0.002) and a higher FIGO stage ( p = 0.003), and were significantly correlated with CDK9 expression ( p = 0.018) and inversely with pCDK9 detection ( p = 0.014). Increased caspase-8 levels corresponded to improved RFS ( p = 0.005), DMFS ( p = 0.038) and CSS ( p = 0.017) in the univariate analyses. Low CDK9 expression was associated with worse RFS ( p = 0.008), CSS ( p = 0.015) and OS ( p = 0.007), but not DMFS ( p = 0.083), and remained a significant prognosticator for RFS ( p = 0.003) and CSS ( p = 0.009) in the multivariate analyses. Furthermore, low pCDK9 staining was significantly associated with superior RFS ( p = 0.004) and DMFS ( p = 0.001), and increased CSS ( p = 0.022), and remained significant for these endpoints in the multivariate analyses. Conclusion: Increased caspase-8 and CDK9 levels correlate with improved disease-related outcomes in cervical cancer patients treated with CRT, whereas elevated pCDK9 levels predict worse survival in this patient population.